Protara Therapeutics, Inc.
corporate_fare Company Profile
Protara Therapeutics, Inc. (NASDAQ:TARA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for TARA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for TARA spans 8-K, 10-Q, 4, 144.
Recent high-impact activity:
- Protara Q3 Loss Widens to $21.7M; Buys Novex Manufacturing Assets for $8.75M
- Q3 Cash Drops to $143M as Net Loss Widens to $21.7M; STARBORN-1 Enrollment Slips to 1Q 2027
- Protara Q2 Loss Widens to $21.7M; Cash Runway Extends into 2028 but Burn Accelerates
- Protara Q2 2026: $161.9M Cash Runway and Pipeline Milestones on Track
- Protara Reports Q2 Cash of $162M, Advances Bladder Cancer and Rare Disease Programs
Financial Snapshot
Short Interest & Short Volume
2.87 days to coverFINRA reported short interest of 3,236,659 shares in TARA as of the October 30, 2026 settlement, a 46.9% decrease from the prior period — about 2.9 days to cover at its recent average daily volume. On November 20, 2026, 54.8% of TARA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for TARA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-15.
At-The-Market Offering Launched · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →